LMY-920 for Treatment of Relapsed or Refractory Myeloma

Since CAR-T cell treatment of refractory myeloma has shown success, based on preclinical data, we posit that CAR-T cells expressing B-cell activating factor (BAFF) can become another strategy to treat refractory myeloma, even after relapse following BCMA targeting CAR-T cell treatment. This will be phase 1 study of BAFF ligand CAR-T cells in relapsed and refractory myeloma.

Trial Details

NCT ID
NCT05546723
Phase
PHASE1
Sponsor
Luminary Therapeutics
Status
RECRUITING
Cancer Type
Relapsed/Refractory Multiple Myeloma
Interventions
  • Autologous CAR-T cell therapy expressing the BAFF-ligand.
Locations (sample)
  • Cleveland, Ohio, United States|41.4995,-81.69541

Key Eligibility Criteria

  • Subjects must have histologically confirmed myeloma relapsed or refractory after 3 or more lines of therapy including an immunomodulatory agent, a …
  • No evidence of CNS myeloma.
  • Male or female \> 18 years of age.
  • ECOG Performance status ≤ 2.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Relapsed/Refractory Multiple Myeloma Trials on Trialify →